Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

Study identifies small molecule inhibitors of SARS-CoV-2 which block key cellular kinases

Antiviral drug screen of kinase inhibitors, which was done by researchers from the University of California and Cedars-Sinai Medical Center, identified cellular signaling pathways critical for SARS-CoV-2 replication and revealed an important mechanism of host-pathogen interaction vital for further drug research. Their results are available on the bioRxiv* preprint server.

28 Jun 2020

Repurposing immunosuppressants to manage COVID-19

It might seem paradoxical to suggest immunosuppression could play a role in managing COVID-19. The seemingly logical therapeutic option for this disease would be an antiviral.

18 Jun 2020

Targeted therapy shows immense benefit for patients with early stage NSCLC

According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.

29 May 2020

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Takeda Pharmaceutical Company Limited today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology, May 29-31 and the 25th Virtual Congress of the European Hematology Association, June 11-14.

18 May 2020

A new combinatorial therapy for treatment of liver cancer

In the latest issue of Molecular Therapy, Skoltech and MIT researchers have published a new combinatorial therapy for the treatment of liver cancer.

20 Apr 2020

Singapore researchers find common therapeutic vulnerability for a deadly blood cancer

CML is a blood cancer that can be controlled by continuously taking an expensive type of medicine called a tyrosine kinase inhibitor (TKI). In almost all patients, stopping TKI treatment results in recurrence of CML.

18 Mar 2020

Research could provide more effective way to treat brain swelling after stroke

Cases of potentially deadly brain damage as a result of stroke could be reduced after new research identified a pathway in the brain that causes swelling, and which responds to an innovative treatment.

2 Mar 2020

Cancer drug shows promise in battling Parkinson’s disease

Parkinson’s disease (PD) is a lifelong condition that affects the nerve cells in the brain that produce dopamine. As a result, people with this neurodegenerative disease experience tremors, changes in speech, gait issues, and muscle rigidity. Though it has no cure, a new drug used to treat cancer shows promise in treating Parkinson’s.

17 Dec 2019

Study shows nilotinib drug is safe and well tolerated in patients with Parkinson's disease

A clinical trial investigating the repurposed cancer drug nilotinib in people with Parkinson's disease finds that it is reasonably safe and well tolerated.

17 Dec 2019

Modifying a cancer drug has created a new agent for multi-resistant infections

Researchers have modified a cancer drug to create an agent that is effective at treating multi-drug-resistant infections.

16 Dec 2019

Treatment combination improves survival in advanced HER2-positive breast cancer patients

Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial.

11 Dec 2019

Scientists highlight the benefits of Droplet Digital PCR technology at the 2019 ASH meeting

Scientists will present more than 40 abstracts highlighting research driven in part by Bio-Rad Laboratories' Droplet Digital PCR (ddPCR) technology at the 2019 American Society of Hematology (ASH) meeting in Orlando Florida, December 7-10.

10 Dec 2019

New strategies needed to manage ibrutinib-related toxicities in CLL patients, study suggests

New findings by Yale Cancer Center and Smilow Cancer Hospital researchers show that as the use of the drug ibrutinib climbs in patients with chronic lymphocytic leukemia, so do the rates of patients who stop taking the drug.

9 Dec 2019

Relapsed mantle cell lymphoma patients may benefit from CAR T-cell therapy

A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.

9 Dec 2019

Ibrutinib-based therapy provides superior clinical outcomes in majority of CLL patients

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) today announced results from an extended follow-up analysis of patients in its randomized Phase 3 clinical trial, E1912.

8 Dec 2019

New treatment could make passing kidney stones faster and less painful

Every year, more than half a million Americans visit the emergency room for kidney stone problems. In most cases, the stones eventually pass out of the body on their own, but the process can be excruciatingly painful.

2 Dec 2019

Juvenile immune arthritis – new treatments wanted

Juvenile immune arthritis (JIA) is a severely undertreated condition, and new medications are badly needed to relieve the signs and symptoms of the illness, according to a new study presented at the 2019 ACR/ARP Annual Meeting.

11 Nov 2019

UCLA researchers discover new way to eliminate leukemia stem cells

The introduction of the drug imatinib in 2001 revolutionized the treatment of a type of cancer called chronic myelogenous leukemia. In more than 80% of people with CML who received the drug, the disease went into complete remission.

15 Oct 2019

RTKI drugs may not significantly improve survival rates of patients during radiotherapy

Taking certain cancer-fighting drugs while undergoing radiation therapy may not increase survival for patients, but may, instead, increase side effects, according to a team of researchers. The drugs, however, may be beneficial for patients who are not undergoing radiation therapy.

10 Oct 2019

Study may help in personalizing treatment for lung cancer, develop new drugs

Researchers at the University of Copenhagen have used highly sophisticated molecular analyses to identify key proteins in the signaling pathways that cancers use to spread in the body.

4 Oct 2019